STOCK TITAN

Cooper - COO STOCK NEWS

Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.

Overview of CooperCompanies

CooperCompanies (NYSE: COO) is a globally recognized medical device company dedicated to enhancing quality of life through innovative healthcare solutions. Headquartered in San Ramon, California, the company operates through two primary business units: CooperVision and CooperSurgical. With a presence in over 130 countries and a workforce exceeding 15,000 employees, CooperCompanies combines cutting-edge technology with a mission-driven approach to address critical healthcare needs.

CooperVision: Transforming Vision Care

CooperVision is a leader in the contact lens industry, offering a comprehensive portfolio of products designed to improve vision for millions of people worldwide. Its product range includes spherical, multifocal, and toric lenses, as well as specialty lenses crafted from advanced materials like silicone hydrogel. These lenses cater to diverse vision correction needs, such as astigmatism and presbyopia, and are available under well-known brands like Biofinity, MyDay, and Clariti.

What sets CooperVision apart is its commitment to innovation and practitioner support. The company collaborates closely with eye care professionals to deliver tailored solutions that enhance patient outcomes. Its specialty lens portfolio, one of the most extensive globally, underscores its dedication to addressing complex vision challenges. As a key player in the vision care market, CooperVision competes with industry giants like Johnson & Johnson and Alcon, leveraging its expertise and product diversity to maintain a strong market share.

CooperSurgical: Advancing Women’s Health

CooperSurgical focuses on improving healthcare delivery for women by providing a wide array of medical devices and treatment options. Its offerings span fertility treatments, reproductive care, and general women’s health solutions. The company is particularly notable for its comprehensive coverage of the in vitro fertilization (IVF) cycle, making it a trusted partner for fertility clinics worldwide.

Key products include the Paragard hormone-free intrauterine device (IUD), which holds a significant share of the U.S. IUD market, and innovative surgical technologies like the ONETRAC™ portfolio of retractors. CooperSurgical’s dedication to addressing critical healthcare moments for women, babies, and families positions it as a leader in its field.

Global Reach and Market Presence

CooperCompanies has established a robust global footprint, with products sold in over 130 countries. Its dual focus on vision care and women’s health not only diversifies its revenue streams but also mitigates risks associated with market-specific challenges. The company’s strategic acquisitions, such as the integration of obp Surgical, further strengthen its product portfolio and market presence.

Commitment to Innovation and Quality

Innovation is at the core of Cooper’s operations. The company invests heavily in research and development to stay ahead in the competitive medical device landscape. Its focus on high-quality, clinically relevant products ensures that it meets the evolving needs of healthcare providers and patients alike. Additionally, Cooper’s adherence to stringent regulatory standards, including the EU Medical Devices Regulation (MDR), underscores its commitment to safety and compliance.

Challenges and Opportunities

While CooperCompanies enjoys a strong market position, it faces challenges such as regulatory complexities, supply chain disruptions, and intense competition. However, its diversified portfolio and strategic focus on high-growth areas like specialty contact lenses and fertility solutions provide significant opportunities for sustained growth. The company’s ability to integrate acquisitions effectively and innovate continuously will be crucial to its long-term success.

Conclusion

CooperCompanies exemplifies a balanced approach to healthcare innovation, combining a strong product portfolio with a commitment to improving lives. Its leadership in vision care and women’s health, coupled with a global reach and focus on quality, positions it as a key player in the medical device industry. Investors and stakeholders can view Cooper as a company that not only addresses current healthcare needs but is also well-equipped to adapt to future challenges and opportunities.

Rhea-AI Summary
CooperCompanies (COO) announces a four-for-one stock split effective February 16, 2024, to enhance accessibility for employees and investors. Trading to start on a split-adjusted basis on February 20, 2024. The split was previously approved by the board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
-
Rhea-AI Summary
COO announces testing services for CBR families to proactively seek additional information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
Rhea-AI Summary
CooperCompanies (COO) will report its first quarter 2024 financial results on February 29, 2024, at 4:15 PM ET. The Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 5337119. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
Rhea-AI Summary
CooperCompanies (Nasdaq: COO) to participate at J.P. Morgan Healthcare Conference on January 9, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
conferences
-
Rhea-AI Summary
Cooper Companies (Nasdaq: COO) to hold annual meeting of stockholders on March 19, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
-
Rhea-AI Summary
CooperCompanies (Nasdaq: COO) announced fiscal fourth quarter 2023 revenue of $927.1 million, up 9%, with a GAAP diluted EPS of $1.70, up 29%. Fiscal year 2023 revenue was $3.6 billion, up 9%. The company's board approved a four-for-one stock split, and fiscal 2024 financial guidance includes a total revenue of $3,809 - $3,877 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
Rhea-AI Summary
CooperCompanies (Nasdaq: COO) appoints Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius brings a wealth of experience from his tenure as CEO and President of McCormick and Company, as well as his roles in other global organizations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
management
-
Rhea-AI Summary
CooperCompanies (Nasdaq: COO) will report Q4 and full year 2023 financial results on December 7, 2023, at 4:15 PM ET. A conference call will be held at 5:00 PM ET to discuss the results and current corporate developments. Dial-in number: 800-715-9871, conference ID: 3206652. Audio webcast available at http://investor.coopercos.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
none
-
Rhea-AI Summary
CooperCompanies has completed the acquisition of select Cook Medical assets for a purchase price of $300 million. The acquired assets are focused on the obstetrics, doppler monitoring, and gynecology surgery markets. The assets generated $56 million in revenue in the past twelve months and are expected to contribute to a 5-7% year-over-year revenue growth in fiscal year 2024. The transaction is expected to be accretive to non-GAAP gross and operating margins and non-GAAP earnings per share by approximately $0.20.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.29%
Tags
Rhea-AI Summary
CooperCompanies will transfer its listing from NYSE to Nasdaq, trading as a Nasdaq-listed company starting September 26, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
none

FAQ

What is the current stock price of Cooper (COO)?

The current stock price of Cooper (COO) is $77.9 as of April 9, 2025.

What is the market cap of Cooper (COO)?

The market cap of Cooper (COO) is approximately 14.1B.

What are the main business segments of CooperCompanies?

CooperCompanies operates through two primary segments: CooperVision, focusing on vision care, and CooperSurgical, specializing in women's health and fertility solutions.

How does CooperVision differentiate itself in the contact lens market?

CooperVision offers a diverse range of high-quality lenses, including specialty lenses for complex vision needs, and collaborates closely with eye care professionals.

What products does CooperSurgical offer?

CooperSurgical provides medical devices for fertility treatments, reproductive care, and general women’s health, including hormone-free IUDs and IVF-related technologies.

What challenges does CooperCompanies face?

Cooper faces challenges such as regulatory compliance, market competition, and supply chain disruptions but mitigates risks through diversification and innovation.

In which countries does CooperCompanies operate?

CooperCompanies has a global presence, with products sold in over 130 countries.

What is CooperCompanies’ approach to innovation?

The company invests heavily in R&D to develop high-quality, clinically relevant products and maintains compliance with stringent regulatory standards.

How does CooperCompanies generate revenue?

Revenue is primarily generated through the sale of medical devices in vision care and women’s health, targeting both healthcare providers and end consumers.

What makes CooperSurgical a leader in fertility solutions?

CooperSurgical offers comprehensive IVF cycle coverage and innovative products like the hormone-free Paragard IUD, making it a trusted partner for fertility clinics.
Cooper

Nasdaq:COO

COO Rankings

COO Stock Data

14.10B
198.73M
0.61%
100.99%
1.54%
Medical Instruments & Supplies
Ophthalmic Goods
Link
United States
SAN RAMON